Advertisement
Canada markets closed

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7300
    +0.0002 (+0.03%)
     

  • CRUDE OIL

    82.61
    -0.20 (-0.24%)
     

  • Bitcoin CAD

    87,775.42
    -3,715.14 (-4.06%)
     

  • CMC Crypto 200

    1,392.19
    -31.91 (-2.24%)
     

  • GOLD FUTURES

    2,331.70
    -6.70 (-0.29%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,468.50
    -196.00 (-1.11%)
     

  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    37,879.60
    -580.48 (-1.51%)
     

  • CAD/EUR

    0.6816
    -0.0003 (-0.04%)
     

Will Edwards Lifesciences (EW) Gain on Rising Earnings Estimates?

Zacks Equity Research

Edwards Lifesciences (EW) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company.

The upward trend in estimate revisions for this medical device maker reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- has this insight at its core.

The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.

For Edwards Lifesciences, there has been strong agreement among the covering analysts in raising earnings estimates, which has helped push consensus estimates considerably higher for the next quarter and full year.

ADVERTISEMENT

The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:

12 Month EPS

Current-Quarter Estimate Revisions

For the current quarter, the company is expected to earn $1.48 per share, which is a change of +26.5% from the year-ago reported number.

Over the last 30 days, nine estimates have moved higher for Edwards Lifesciences compared to no negative revisions. As a result, the Zacks Consensus Estimate has increased 5.89%.

Current-Year Estimate Revisions

The company is expected to earn $5.57 per share for the full year, which represents a change of +18.51% from the prior-year number.

There has been an encouraging trend in estimate revisions for the current year as well. Over the past month, 11 estimates have moved up for Edwards Lifesciences versus no negative revisions. This has pushed the consensus estimate 5.03% higher.

Favorable Zacks Rank

Thanks to promising estimate revisions, Edwards Lifesciences currently carries a Zacks Rank #2 (Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.

Bottom Line

Edwards Lifesciences shares have added 7.1% over the past four weeks, suggesting that investors are betting on its impressive estimate revisions. So, you may consider adding it to your portfolio right away to benefit from its earnings growth prospects.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.